Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomarkers In Orphan Studies Still Need Past Experience, FDA Says

Executive Summary

Rare Disease groups work to finalize white paper on accelerated approval, but FDA questions whether a rules-based biomarker qualification process is possible.


Related Content

Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says
Regulatory Flexibility For Rare Diseases: How Do You Routinize Elasticity?
Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard
As Orphan Drugs Gain More Attention, FDA Releases Development Guidance
Regulatory Freelancing: Rare Disease Group Hopes To Shape FDA Guidance
Should FDA Be Forced To Consider Development Time And Cost?
FDA To Provide Expedited Approval Desktop Reference
FDASIA Is Signed, Not That White House Wanted Anyone To Notice
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts